Boehringer Ingelheim (Canada) Ltd., has received approval of their product PRASCEND® from the Veterinary Drug Directorate of Health Canada for the treatment of clinical signs associated with pituitary pars intermedia dysfunction (PPID) in horses, also known as Equine Cushing’s Disease.

PRASCEND®, administered in tablet form, can improve the quality of life for horses with the disease by managing their clinical signs and decreasing the risks of complications, including those that can be life-threatening.

It is estimated that one in seven horses over age 15 has PPID, although horses as young as seven can develop it. In addition, up to 70 percent of clinical laminitis cases may also be affected by underlying PPID. 

Symptoms include abnormal hair growth, abnormal sweating, weight loss, muscle wasting, abnormal fat distribution, lethargy, laminitis, polyuria/polydipsia, and chronic or recurrent infections. 

While PPID is not curable, PRASCEND® provides medication to better manage the symptoms and provide a quality of life for the horse. The approval from Health Canada assures consumers that PRASCENT® has met all the regulatory standards in terms of quality, purity, and consistency. 

For more information contact your veterinarian or your Boehringer Ingelhem (Canada) Ltd., animal health representative.

The information in this feature was provided by participating businesses. The products and services mentioned have not been tested or endorsed by this publication. Please contact the businesses indicated in the feature for more information.